Latest Articles about SIGA

Strong Quarter for Merck KGaA - Analyst Blog

Zacks Equity Research — Fri, 08 Mar 2013 19:40:01 Z

Merck KGaA ( MKGAF ) reported fourth quarter 2012 earnings per American Depository Receipt (ADR) of $2.66, up 18.8% year over year. Revenues for the reported quarter were up 8% year over

Positive Results on UCB's Vimpat - Analyst Blog

Zacks Equity Research — Thu, 07 Mar 2013 02:55:13 Z

UCB ( UCBJF ) recently received good news with the company announcing positive results on Vimpat (lacosamide) from a phase III study being conducted to support the label expansion of the

UCB In-licenses Parkinson's Drug - Analyst Blog

Zacks Equity Research — Sat, 02 Mar 2013 02:00:01 Z

UCB ( UCBJF ) recently announced that it has licensed exclusive global rights to tozadenant (SYN115) for Parkinson's disease from Biotie Therapies. The Candidate Tozadenant is an orally

UCB Beats on Revs - Analyst Blog

Zacks Equity Research — Thu, 28 Feb 2013 21:28:00 Z

UCB ( UCBJF ) reported 2012 earnings per share of $2.80, up 12% on a reported basis but down 4% at constant exchange rates (CER). Revenues for the year 2012 were approximately $4,450.7

Mylan Beats by a Penny, Guides Up - Analyst Blog

Zacks Equity Research — Thu, 28 Feb 2013 18:40:01 Z

Mylan, Inc. 's ( MYL ) fourth-quarter 2012 earnings (excluding special items) of 65 cents per share beat the Zacks Consensus Estimate by a penny. The earnings beat was primarily

Ariad Reports in line 4Q Loss - Analyst Blog

Zacks Equity Research — Wed, 27 Feb 2013 20:10:01 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) reported fourth quarter loss of 36 cents per share, compared with the year-ago loss of 23 cents per share. The Zacks Consensus Estimate for the fourth

Questcor Beats Overall - Analyst Blog

Zacks Equity Research — Wed, 27 Feb 2013 20:00:01 Z

Questcor Pharmaceuticals Inc. ( QCOR ) reported fourth quarter 2012 adjusted earnings per share of $1.09, up 132% from the year-ago period. Earnings surpassed the Zacks Consensus Estimate

Label Expansion for Astellas - Analyst Blog

Zacks Equity Research — Tue, 26 Feb 2013 02:15:01 Z

Astellas Pharmaceuticals Inc. ( ALPMY ) and Kyowa Hakko Kirin Co., Ltd. recently announced the receipt of Japan's Ministry of Health, Labour and Welfare (MHLW) approval for the drugs,

NPS Pharma Incurs Wider 4Q Loss - Analyst Blog

Zacks Equity Research — Mon, 25 Feb 2013 20:00:01 Z

NPS Pharmaceuticals, Inc. ( NPSP ) reported fourth quarter 2012 net loss per share of 14 cents, wider than the Zacks Consensus Estimate of a loss of 9 cents and the year-ago loss of 10

UCB - ConfometRx Collaborate - Analyst Blog

Zacks Equity Research — Fri, 22 Feb 2013 02:40:01 Z

UCB ( UCBJF ) recently entered into an agreement with ConfometRx for the discovery of novel medicines in the neuroscience therapeutic area. This research and development (R&D)

A Judge's Ruling Could Send these Stocks Soaring Very Soon

David Sterman — Mon, 20 Jun 2011 19:00:00 Z

There's a drama unfolding in the health care field that is as dramatic as the daytime soap operas. Lots of "he said, she said" has been tossed around, and just to add a little spice, a

I've Found a Handful of Companies That Could Grow 200% -- or More -- by 2012

David Sterman — Fri, 04 Mar 2011 19:00:00 Z

Early-stage companies spend many years planning for the day when everything clicks. For a number of them, 2012 could be the year when all their hard work pays off. So I decided to look at

5 Top Stocks Under $5

David Sterman — Mon, 21 Feb 2011 22:00:00 Z

I'm a big fan of low-priced stocks -- especially those that are under $5 a share. At that level, mostmutual fund managers are restricted from owning them. But if growth plans pan out andshares

Squeeze ideas: Highly Shorted Stocks With Improving Analyst Sentiment

Kapitall — Sat, 20 Nov 2010 02:28:22 Z

Compiled by Luis Gonzalez : The following is a list of stocks with high short float. Short-sellers seem to think there's more downside to these names, but Wall Street analysts disagree. All of

3 Insider Stocks That Could Pop

David Sterman — Wed, 10 Nov 2010 18:00:31 Z

As earnings season winds down, insider activity heats up. That's because insiders (classified as company executives, directors and beneficial owners) get the green light to buy or sell their